Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure. Influencing Factors, Detection of Left Ventricular Systolic Dysfunction, and Prediction of Death

Journal of the American College of Cardiology

Volumn 53, Issue 19, 2009, Pages 1783-1790

  Moertl, Deddo ^a   Berger, Rudolf ^a   Struck, Joachim ^b   Gleiss, Andreas ^a   Hammer, Alexandra ^a   Morgenthaler, Nils G ^b   Bergmann, Andreas ^b   Huelsmann, Martin ^a   Pacher, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BRAHMS AG   (Germany)

Author keywords

chronic heart failure; natriuretic peptides; prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PRO B TYPE NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANKLE EDEMA; ARTICLE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC DYSFUNCTION;

ATRIAL NATRIURETIC FACTOR; CONFIDENCE INTERVALS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, SYSTOLIC; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 65349126493     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.057     Document Type: Article

References (34)

1. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., and Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure. BMJ 324 (2002) 1498-1500
2. Sakurai S., Adachi H., Hasegawa A., et al. Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction. Heart 89 (2003) 661-662
3. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625-627
4. Felker G.M., Petersen J.W., and Mark D.B. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 175 (2006) 611-617
5. Ala-Kopsala M., Magga J., Peuhkurinen K., et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 50 (2004) 1576-1588
6. Seidler T., Pemberton C., Yandle T., Espiner E., Nicholls G., and Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 255 (1999) 495-501
7. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49 (2007) 1071-1078
8. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 96 (1997) 509-516
9. Dickstein K., Larsen A.I., Bonarjee V., Thoresen M., Aarsland T., and Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 76 (1995) 679-683
10. Dickstein K., Aarsland T., and Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Card Fail 3 (1997) 83-89
11. Wijbenga J.A., Balk A.H., Boomsma F., Man in't Veld A.J., and Hall C. Cardiac peptides differ in their response to exercise. Eur Heart J 20 (1999) 1424-1428
12. Choy A.M., Darbar D., Lang C.C., et al. Detection of left ventricular dysfunction after acute myocardial infarction. Br Heart J 72 (1994) 16-22
13. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
14. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., and Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310 (2001) 193-197
15. Morgenthaler N.G., Struck J., Thomas B., and Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50 (2004) 234-236
16. Luchner A., Hengstenberg C., Lowel H., Riegger G.A., Schunkert H., and Holmer S. Effect of compensated renal dysfunction on approved heart failure markers. Hypertension 46 (2005) 118-123
17. Vickery S., Price C.P., John R.I., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD. Am J Kidney Dis 46 (2005) 610-620
18. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
19. Heinze G., and Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 71 (2003) 155-163
20. Shaffer J. Modified sequentially rejective multiple test procedures. J Am Stat Assoc 81 (1985) 826-831
21. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
22. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation 108 (2003) 275-281
23. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
24. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
25. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. J Am Coll Cardiol 47 (2006) 345-353
26. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. J Am Coll Cardiol 47 (2006) 91-97
27. Elmas E., Brueckmann M., Lang S., et al. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int J Cardiol 128 (2008) 244-249
28. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13 (2007) 42-49
29. Squire I.B., O'Brien R.J., Demme B., Davies J.E., and Ng L.L. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond) 107 (2004) 309-316
30. Baertschi A.J., Monnier D., Schmidt U., Levitan E.S., Fakan S., and Roatti A. Acid prohormone sequence determines size, shape, and docking of secretory vesicles in atrial myocytes. Circ Res 89 (2001) E23-E29
31. Daggubati S., Parks J.R., Overton R.M., Cintron G., Schocken D.D., and Vesely D.L. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 36 (1997) 246-255
32. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond) 97 (1999) 255-258
33. Kimura K., Yamaguchi Y., Horii M., et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 63 (2007) 699-702
34. Laukkanen J.A., Kurl S., Ala-Kopsala M., et al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J 27 (2006) 1230-1237